BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 8
• 9
• 10
• 11
• 12
• 15
• 16
• 17
• 18
• 19
• 22
• 23
• 24
• 25
• 26
• 29
• 30
• 31

• 

  Scrutiny of WuXi Raises Potential Opportunities for Indian CDMOs

  As congressional pressure increases on WuXi AppTec and other China-based companies over alleged ties to the Chinese government, India’s contract development and manufacturing organization sector could benefit.

  July 3, 2024

   · 

  4 min read

   · 

  Tyler Patchen
• 

  Drug Pricing

  Biden, Sanders Call on Novo Nordisk and Eli Lilly to Lower Weight-Loss Drug Prices

  President Joe Biden and Sen. Bernie Sanders in a Tuesday op-ed in USA Today called on Novo Nordisk and Eli Lilly to “stop ripping off Americans” with “unconscionably high prices” for their GLP-1 medicines.

  July 3, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug Development

  J&J, Legend’s Phase III Win Cements Carvykti as Earlier-Line Multiple Myeloma Treatment

  Johnson & Johnson and Legend Biotech’s Carvykti cell therapy significantly improved survival in patients with multiple myeloma when used in the second-line setting, the companies announced on Tuesday.

  July 3, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  News

  Taysha Shares Positive Rett Results in Bid to Move Past Roadblocks

  Taysha Gene Therapies looks to move past its pipeline culls and staff reductions by moving its lead asset into a possible billion-dollar market.
  

  July 3, 2024

   · 

  3 min read

   · 

  Tyler Patchen
• 

  Podcasts

  FDA Approves Lilly’s Donanemab While Rejections Highlight Manufacturing Issues

  Two CRLs from the FDA last week cited concerns with third-party manufacturers, while Indian CDMOs may make a bid for U.S. business if there is a decoupling from Chinese companies under the BIOSECURE Act.

  July 3, 2024

   · 

  1 min read

   · 

  Jef Akst
• 

  Policy

  BIOSECURE Act Erodes Industry Confidence in Chinese Contractors: Report

  Despite an uncertain legislative path to becoming law, the BIOSECURE Act has already impacted the biopharma industry’s confidence in Chinese service providers and prompted efforts to diversify manufacturing partners.

  July 3, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Deals

  GSK Pays $430M Upfront for CureVac’s COVID-19, Flu mRNA Vaccines

  GSK on Wednesday restructured its contract with CureVac to gain access to the biotech’s influenza and COVID-19 programs for $430 million upfront and up to $1.13 billion in future payments.

  July 3, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  Owkin, an AI-Biotech Unicorn, Brings Its Cutting-Edge AI to Germany, Austria and Switzerland to Accelerate Research

  July 3, 2024

   · 

  5 min read
• Press Releases

  Hansa Biopharma to host Q2 2024 interim results conference call

  July 3, 2024

   · 

  2 min read
• Press Releases

  Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 3, 2024

  July 3, 2024

   · 

  2 min read